EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Comparison of IGLV2 ‐14 light chain sequences of patients with AL amyloidosis or multiple myeloma

Natalie Berghaus iD, Sarah Schreiner, Alexandra M Poos, Marc S Raab, Hartmut Goldschmidt, Elias K Mai, Hans-Jürgen Salwender, Helga Bernhard, Lorenz Thurner, Carsten Müller-Tidow, Niels Weinhold, Ute Hegenbart und 2 weitere

The FEBS Journal · 2023

DOI: 10.1111/febs.16805 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FEBS Journal, 2023. Verfasst von Natalie Berghaus und 13 weiteren Autor:innen. Beteiligte Einrichtung: Medical Department V, Amyloidosis Center, Heidelberg University Hospital, Germany. Hauptthemen laut MEDLINE: Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Amyloidosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Light chain amyloidosis (AL) is one of the most common forms of systemic amyloidosis and is caused by the deposition of insoluble fibrils derived from misfolded and aggregated immunoglobulin light chains (LC). To uncover the causes leading to this aggregation, we compared AL LC sequences with those of patients with the related disease multiple myeloma (MM), which do not aggregate in insoluble fibrils in vivo . IGLV2‐14 is one of the most common AL‐associated IGLV subfamilies. Here, we analysed IGLV2‐14 LC sequences of 13 AL and eight MM patients in detail. We found that AL‐associated LCs presented a lower median mutation count (7.0 vs. 11.5 in MM; P = 0.045), as well as an overall composition of less charged amino acids than MM LCs. However, we did not find a mutation that was present in ≥ 50% of the AL and not in the MM sequences. Furthermore, we did not find a significant difference in the isoelectric point (pI) in general, suggesting similar stability of the LCs in AL and MM. However, the subgroup of patients without a detectable heavy chain stood out. Surprisingly, they are characterized by an increase in mutation count (median 7.0 vs. 5.5) and pI (median 7.82 vs. 6.44, P = 0.043). In conclusion, our data suggest that the amount of mutations and the introduction of charges play a crucial role in AL fibril formation, as well as the absence or presence of a potential heavy chain binding partner.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulin Light-chain AmyloidosisMultiple MyelomaAmyloidosisHumansImmunoglobulin Light ChainsMutationAmyloid

Stichwörter der Autor:innen

amyloidosishaematology-oncologylight chainsmultiple myelomasequencing

Substanzen

Immunoglobulin Light ChainsAmyloid

Autor:innen und Institutionen

  • Medical Department V, Amyloidosis Center, Heidelberg University Hospital, Germany.
  • Medical Department V, Section of Multiple Myeloma, Heidelberg University Hospital, Germany.
  • National Centre for Tumor Diseases (NCT), Heidelberg, Germany.
  • Asklepios tumor center Hamburg, AK Altona and AK St. Georg, Hamburg, Germany.
  • Medical Department V, Hematology/Oncology, Hospital Darmstadt GmbH, Germany.
  • Internal Medicine I, University Hospital Saarland, Homburg/ Saar, Germany.

ORCID-Profile: Natalie Berghaus, Stefan O Schönland

Förderung

  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Berghaus, N., Schreiner, S., Poos, A. M., Raab, M. S., Goldschmidt, H., Mai, E. K., Salwender, H. J., Bernhard, H., Thurner, L., Müller-Tidow, C., Weinhold, N., Hegenbart, U., Schönland, S. O., & Huhn, S. (2023). Comparison of IGLV2 ‐14 light chain sequences of patients with AL amyloidosis or multiple myeloma. The FEBS Journal. https://doi.org/10.1111/febs.16805

Vancouver

Berghaus N, Schreiner S, Poos AM, Raab MS, Goldschmidt H, Mai EK, et al. Comparison of IGLV2 ‐14 light chain sequences of patients with AL amyloidosis or multiple myeloma. The FEBS Journal. 2023. doi:10.1111/febs.16805

BibTeX
@article{Berghaus2023,
  author = {Berghaus, Natalie and Schreiner, Sarah and Poos, Alexandra M and Raab, Marc S and Goldschmidt, Hartmut and Mai, Elias K and Salwender, Hans-Jürgen and Bernhard, Helga and Thurner, Lorenz and Müller-Tidow, Carsten and Weinhold, Niels and Hegenbart, Ute and Schönland, Stefan O and Huhn, Stefanie},
  title = {Comparison of IGLV2 ‐14 light chain sequences of patients with AL amyloidosis or multiple myeloma},
  journal = {The FEBS Journal},
  year = {2023},
  doi = {10.1111/febs.16805}
}
Kostenlos starten →